Review
Pharmacology & Pharmacy
Michele Provenzano, Michele Andreucci, Carlo Garofalo, Roberto Minutolo, Raffaele Serra, Luca De Nicola
Summary: The SONAR trial demonstrated the protective effect of ERA on CKD progression. This has led to an increase in clinical research on ERA in CKD patients, with new phase 3 studies currently underway for glomerular disease patients. Additionally, evaluating the effects of multiple treatments in proteinuric CKD patients, including ERA, within the realm of personalized medicine may be beneficial in identifying optimal treatment options.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Review
Biochemistry & Molecular Biology
Ryosuke Saiki, Kan Katayama, Kaoru Dohi
Summary: Proteinuria is associated with mortality, and nephrotic syndrome is defined by proteinuria and hypoalbuminemia. Genetic kidney diseases have been discovered more frequently with advances in medicine. This review focuses on the study of proteinuria/nephrotic syndrome and other kidney diseases in mouse models, leading to significant progress in understanding genetics and pathophysiology. Future genetic analysis of proteinuric kidney disease/nephrotic syndrome may provide personalized treatment options.
Review
Urology & Nephrology
Yu Sun, Sijia Cui, Yunfeng Hou, Fan Yi
Summary: Disorder of podocyte lipid metabolism is closely associated with various proteinuric kidney diseases, excessive lipid accumulation can lead to cellular dysfunction, ultimately resulting in cell hypertrophy, detachment, and death. Targeting podocyte lipid metabolism may represent a novel therapeutic strategy for patients with proteinuric kidney disease.
Article
Biochemistry & Molecular Biology
Chunping Yu, Hong Zhang, Shuangxin Liu, Ruizhao Li, Xingchen Zhao, Yuanhan Chen, Zhuo Li, Jianchao Ma, Wenjian Wang, Zhiming Ye, Xinling Liang, Li Zhang, Wei Shi
Summary: Podocyte injury is a common feature of chronic kidney disease (CKD). Flot2 has been identified as an important factor in stabilizing the podocin-nephrin complex in lipid rafts, reducing podocyte injury and proteinuria. Flot2 interacts with podocin and nephrin, recruits them into rafts, and ameliorates podocyte injury. Furthermore, Flot2 expression is downregulated in renal biopsies from patients with podocytopathies, suggesting its potential as a therapeutic target for proteinuric kidney disease.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Pediatrics
George W. Burke, Jayanthi Chandar, Junichiro Sageshima, Mariella Ortigosa-Goggins, Pooja Amarapurkar, Alla Mitrofanova, Marissa J. Defreitas, Chryso P. Katsoufis, Wacharee Seeherunvong, Alexandra Centeno, Javier Pagan, Lumen A. Mendez-Castaner, Adela D. Mattiazzi, Warren L. Kupin, Giselle Guerra, Linda J. Chen, Mahmoud Morsi, Jose M. G. Figueiro, Rodrigo Vianna, Carolyn L. Abitbol, David Roth, Alessia Fornoni, Phillip Ruiz, Gaetano Ciancio, Eduardo H. Garin
Summary: Podocyte B7-1 staining in biopsies of KTRs with post-transplant FSGS identifies a subset of patients who may benefit from abatacept.
PEDIATRIC NEPHROLOGY
(2023)
Article
Urology & Nephrology
Wen Shen, Mohammed Alshehri, Sameer Desale, Christopher Wilcox
Summary: Both amiloride and triamterene significantly reduced proteinuria in patients with proteinuric kidney disease, showing positive therapeutic effects. However, hyperkalemia is a safety concern that needs attention.
AMERICAN JOURNAL OF NEPHROLOGY
(2021)
Article
Medicine, Research & Experimental
Jianyong Zhong, Hai -Chun Yang, Elaine L. Shelton, Taiji Matsusaka, Amanda J. Clark, Valery Yermalitsky, Zahra Mashhadi, Linda S. May-Zhang, MacRae F. Linton, Agnes B. Fogo, Annet Kirabo, Sean S. Davies, Valentina Kon
Summary: The study found that patients and animals with proteinuric injury have increased IsoLG-apoAI in their urine, which not only serves as a marker of renal injury, but also directly damages renal cells and has a greater impact on renal lymphatic vessels.
Article
Biology
Stefanos Roumeliotis, Panagiotis Georgianos, Athanasios Roumeliotis, Theodoros Eleftheriadis, Aikaterini Stamou, Vangelis G. Manolopoulos, Stylianos Panagoutsos, Vassilios Liakopoulos
Summary: This study shows that circulating ox-LDL levels amplify the magnitude of the association between proteinuria and progression of DKD in patients with proteinuric DKD.
Article
Multidisciplinary Sciences
Wataru Nishi, Ei Wakamatsu, Hiroaki Machiyama, Ryohei Matsushima, Kensho Saito, Yosuke Yoshida, Tetsushi Nishikawa, Tomohiro Takehara, Hiroko Toyota, Masae Furuhata, Hitoshi Nishijima, Arata Takeuchi, Miyuki Azuma, Makoto Suzuki, Tadashi Yokosuka
Summary: An advanced imaging system has been established to evaluate the clinical effectiveness of immune checkpoint inhibitors (ICIs). This system can digitally evaluate PD-1-mediated T cell suppression by visualizing PD-1 microclusters, allowing for the identification of the most suitable combinations of ICIs.
NATURE COMMUNICATIONS
(2023)
Article
Urology & Nephrology
Hiddo J. L. Heerspink, Gordon Law, Konstantina Psachoulia, Kathleen Connolly, Carl Whatling, Hans Ericsson, Jane Knochel, Eva-Lotte Lindstedt, Iain MacPhee
Summary: The FLAIR study is evaluating the efficacy and safety of AZD5718 in patients with proteinuric CKD, with the primary objective being the dose-response effect of AZD5718 on UACR after the dapagliflozin extension. Key secondary objectives include the dose-response effect of AZD5718 plus current standard of care on UACR and acute effects of treatment on the estimated glomerular filtration rate.
KIDNEY INTERNATIONAL REPORTS
(2021)
Editorial Material
Oncology
Michael R. Pitter, Weiping Zou
Summary: The article demonstrates that immune checkpoint blockade can enhance the response of tumor-specific T cells against tumor cells, effectively increasing tumor cell lysis, and provides scientific rationale for a new generation of cancer treatment targeting the PD-1/PD-L1 signaling pathway in the tumor microenvironment.
Article
Surgery
Filip Cvetkovski, Ronia Razavi, Felix Sellberg, Erik Berglund, David Berglund
Summary: Combined therapy of siplizumab with abatacept or belatacept can effectively suppress T cell proliferation, enhance siplizumab-mediated T cell inhibition, and improve the selective depletion of memory T cells. This combination therapy may be used for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation.
AMERICAN JOURNAL OF TRANSPLANTATION
(2023)
Article
Urology & Nephrology
Rosi Bissinger, Travis Nemkov, Angelo D'Alessandro, Marijke Grau, Thomas Dietz, Bernhard N. Bohnert, Daniel Essigke, Matthias Woern, Lina Schaefer, Mengyun Xiao, Jonathan M. Beirne, M. Zaher Kalo, Anja Schork, Tamam Bakchoul, Kingsley Omage, Lingsi Kong, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Birgit Fehrenbacher, Martin Schaller, Achal Dhariwal, Andreas L. Birkenfeld, Florian Grahammer, Syed M. Qadri, Ferruh Artunc
Summary: This study using mouse models demonstrates the development of chronic kidney disease-associated anemia is linked to altered red blood cell metabolism, reduced RBC deformability, and enhanced cell death.
KIDNEY INTERNATIONAL
(2021)
Review
Endocrinology & Metabolism
Jiayi Yan, Jue Wang, John Cijiang He, Yifei Zhong
Summary: The incidence and prevalence of chronic kidney disease (CKD) are increasing worldwide and pose a significant public health burden. SIRT1, a NAD+-dependent deacetylase, has protective effects on the kidney by regulating fibrosis, apoptosis, senescence, oxidative stress, inflammation, and aging. This narrative review provides an overview of the recent progress on the role of SIRT1 and its downstream pathways in CKD and discusses potential therapeutic approaches by activating the SIRT1-related pathway in CKD patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
William E. Russell, Brian N. Bundy, Mark S. Anderson, Laura A. Cooney, Stephen E. Gitelman, Robin S. Goland, Peter A. Gottlieb, Carla J. Greenbaum, Michael J. Haller, Jeffrey P. Krischer, Ingrid M. Libman, Peter S. Linsley, S. Alice Long, Sandra M. Lord, Daniel J. Moore, Wayne Moore, Antoinette M. Moran, Andrew B. Muir, Philip Raskin, Jay S. Skyler, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, Anette-Gabriele Ziegler, Kevan C. Herold
Summary: This study shows that inhibiting lymphocyte costimulation can reduce the decline in beta-cell function in newly diagnosed type 1 diabetes patients. By treating antibody-positive individuals with normal glucose tolerance with abatacept for 12 months, it was found that abatacept can delay or prevent the progression of type 1 diabetes and affect immune and metabolic responses.
